The drug Caplyta, owned by Intra-Cellular Therapies, is being used to treat bipolar disorder and schizophrenia. In 2024, it brought in more than $481 million in sales. 

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.

The companies argue that the U.S. Department of Justice has failed to adequately demonstrate how, and in which regions of the country, the merger would harm competition. They are asking a federal court to throw out the case.

The motion is being advanced by religious groups and hedge funds alike, with the decision to develop a report set to be voted on at the UnitedHealth Group 2025 annual meeting.

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

While artificial intelligence engineers and consultants took the top two spots, physical therapists and advanced practice providers also landed among the 25 fastest growing jobs in the U.S. 

Boston Scientific has agreed to acquire Bolt Medical, a California-based medical device company focused on developing new intravascular lithotripsy technologies. The news comes less than one year after Johnson & Johnson acquired IVL pioneers Shockwave Medical for $13 billion.

A new final rule from the Consumer Financial Protection Bureau bans reporting agencies from including medical debts on credit reports or factoring them into credit scores.